Integrated bioinformatics–cheminformatics approach toward locating pseudo‐potential antiviral marine alkaloids against SARS‐CoV‐2‐Mpro

Shasank S. Swain,Satya R. Singh,Alaka Sahoo,Pritam Kumar Panda,Tahziba Hussain,Sanghamitra Pati
DOI: https://doi.org/10.1002/prot.26341
2022-04-13
Abstract:The emergence of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) with the most contagious variants, alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2) and Omicron (B.1.1.529) has continuously added a higher number of morbidity and mortality, globally. The present integrated bioinformatics‐cheminformatics approach was employed to locate potent antiviral marine alkaloids that could be used against SARS‐CoV‐2. Initially, fifty‐seven antiviral marine alkaloids and two repurposing drugs were selected from an extensive literature review. Then, retrieved the putative target enzyme SARS‐CoV‐2 main protease (SARS‐CoV‐2‐Mpro) from the protein data bank and carried out a virtual screening‐cum‐molecular docking study with all candidates using PyRx 0.8 and AutoDock 4.2 software. Further, the molecular dynamics (MD) simulation of the two most potential alkaloids and a drug docking complex at 100 nanoseconds (with two ligand topology files from PRODRG and ATB server, separately), the MM/PBSA free‐energy and contributions of entropy were investigated. Then, assessed and analyzed the physicochemical‐toxicity‐pharmacokinetics‐drug‐likeness profiles, the frontier molecular orbitals energies (HOMO, LUMO and ΔE) and structural‐activity relationship. Based on binding energy, 8‐hydroxymanzamine (−10.5 kcal/mol) and manzamine A (−10.1 kcal/mol) from all alkaloids with darunavir (−7.9 kcal/mol) and lopinavir (−7.4 kcal/mol) against SARS‐CoV‐2‐Mpro were recorded. The MD simulation (RMSD, RMSF, Rg, H‐bond, MM/PBSA binding energy) illustrated that the 8‐hydroxymanzamine exhibits a static thermodynamic feature than the other two complexes. The predicted physicochemical, toxicity, pharmacokinetics and drug‐likeness profiles also revealed that the 8‐hydroxymanzamine could be used as a potential lead candidate individually and/ or synergistically with darunavir or lopinavir to combat SARS‐CoV‐2 infection after some pharmacological validation.This article is protected by copyright. All rights reserved.
What problem does this paper attempt to address?